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INTRODUCTION [1-8] 
 The discipline of medicinal chemistry is committed to the discovery and 
development of new agents for treating diseases. Most of this activity is directed to new 
natural or synthetic organic compounds.  
Inorganic compounds continue to be important in therapy, e.g., trace elements in 
nutritional therapy, antacids and radiopharmaceuticals but organic molecules with 
increasingly specific pharmacological activities are clearly dominant.  
Development of organic compounds has grown beyond traditional synthetic 
methods. It now includes the exciting new field of biotechnology using the cell’s 
biochemistry to synthesize new compounds.  
Techniques ranging from recombinant DNA and site-directed mutagenesis to 
fusion of cell lines have greatly broadened the possibilities for new entities.  
Medicinal chemistry 
 Medicinal chemistry concerns the discovery, the development, the identification 
and the interpretation of the mode of action of biologically active compounds at the 
molecular level. But the interest of the medicinal chemistry is also concerned with the 
study, identification and synthesis of the metabolic products of drugs and related 
compounds. 
Developments and discoveries in medicinal chemistry 
The pharmacist now dispenses modified human insulin’s that provide more 
convenient dosing schedules, cell-stimulating factors that have changed the dosing 
regimens for chemotherapy, humanized monoclonal antibodies that target specific tissues 
and fused receptors that intercept immune cell-generated cytokines. 
 The process of establishing a new pharmaceutical is very difficult and involves 
the talents of people from variety of disciplines, including chemistry, biochemistry, 
molecular biology, physiology, pharmacology, pharmaceutics and medicine.  
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Medicinal chemistry itself is concerned mainly with the organic, analytical and 
biochemical aspects of this process but the chemist must interact productively with those 
in other disciplines. Thus, medicinal chemistry occupies a strategic position at the 
interface of chemistry and biology.  
 The earliest drug discoveries were made by random sampling of higher plants. 
Some of this sampling, although based on anecdotal evidence, led to the use of such 
crude plant drugs as opium, belladonna and ephedrine that have been important for 
centuries.  
With the accidental discovery of penicillin came the screening of microorganisms 
and the large number of antibiotics from bacterial and fungal sources. Many of these 
antibiotics provided the prototypical structure that the medicinal chemist modified to 
obtain anti-bacterial drugs with better therapeutic profiles. With the changes in federal 
legislation reducing the efficacy requirement for “nutriceutical” the public increasingly is 
using so-called nontraditional or alternative medicinal that are sold over the counter, 
many outside of traditional pharmacy distribution channels.  
 Hundreds of thousands of new organic chemicals are prepared annually 
throughout the world and many of them are entered in to pharmacological screens to 
determine whether they have useful biological activity. This process of random screening 
has been considered inefficient, but it has resulted in the identification of new lead 
compounds whose structures have been optimized to produce clinical agents. Sometimes, 
a lead develops by careful observation of the pharmacological behavior of an existing 
drug.  
The discovery that amantadine protects and treats early influenza A came from a 
general screen for antiviral agents. The use of amantadine in long-term care facilities 
showed that it also could be used to treat parkinsonian disorders. More recently, 
automated high-throughput screening systems utilizing cell culture systems with linked 
enzyme assays and receptor molecules derived from gene cloning have greatly increased 
the efficiency of random screening. It is now practical to screen enormous libraries of 
peptides and nucleic acids obtained from combinatorial chemistry procedures. 
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Molecular design with target tissue   
Rational design, the opposite approach to high-volume screening, is also 
flourishing. Significant advances in x-ray crystallography and nuclear magnetic 
resonance have made it possible to obtain detailed representations of enzymes and other 
drug receptors.  
The techniques of molecular graphics and computational chemistry have provided 
novel chemical structures that have led to new drugs with potent medicinal activities. 
Development of HIV protease inhibitors and angiotensin-converting enzyme (ACE) 
inhibitors came from an understanding of the geometry and chemical character of the 
respective enzyme’s active site.  
Even if the receptor structure is not known in detail, rational approaches based on 
the physiochemical properties of lead compounds can provide new drugs. For example, 
the development of cimetidine as an antinuclear drug involved a careful study of the 
changes in antagonism of H2-histamine receptors induced by varying the physical 
properties of structures. 
Medicinal chemistry is an interdisciplinary science covering a particularly wide 
domain situated at the interface of organic chemistry with life sciences such as 
biochemistry, pharmacology, molecular biology, immunology, pharmacokinetics and 
toxicology on one side and chemistry based disciplines such as physical chemistry, 
crystallography, spectroscopy and computer based information technologies on the other. 
The knowledge of the molecular targets (enzymes, receptors, nucleic acids) has 
benefitted from the progress made in molecular biology, genetic engineering and 
structural biology. For an increasing number of targets the three dimensional structure 
and the precise location of the active site are known.  
The design of new active substances is therefore more and more based on results 
obtained from ligand-receptor modeling studies. One can actually consider the existence 
of a molecular pharmacochemistry making a pair with molecular pharmacology. 
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Principles of medicinal chemistry 
 To provide an understanding of the principles of medicinal chemistry, it is 
necessary to consider the physiochemical properties used to develop new 
pharmacologically active compounds and their mechanism of action, the drug’s 
metabolism including possible biological activities of the metabolites, the importance of 
stereochemistry in drug design, and the methods used to determine what “ space “ a drug 
occupies. 
It is important for the pharmacist and the public to understand the rigor that is 
required for prescription only and FDA approved nonprescription products to be 
approved relative to the nontraditional products.  
It also is important for all people in the health care field and the public to realize 
that whether these nontraditional products are effective as claimed or not many of the 
alternate medicines contain pharmacologically active agents that can potentiate or 
interfere with physician prescribed therapy.  
Objective of medicinal chemistry 
 The objective of medicinal chemistry is design and production of compounds that 
can be used in medicine for the prevention, treatment and cure of human or animal 
disease. Thus medicinal chemistry is a part of pharmacology, this latter being taken in its 
etymological sense. 
 Medicinal chemistry also includes the study of already existing drugs, of their 
pharmacological properties and their structure activity relationships. An official 
definition of medicinal chemistry was given by an IUPAC specialized commission. 
A certain number of terms more or less synonymous with medicinal chemistry are 
used: pharmacochemistry, molecular pharmacochemistry, drug design and selective 
toxicity. The French equivalent to medicinal chemistry is ‘Chimie Therapeutique’ and the 
german one is ‘Arzneimittelforschung’ 
 
K.M.College of Pharmacy                                                                                                   INTRODUCTION 
 
Dept. of Pharmaceutical chemistry                                                                                                      Page 5 
 
  
Steps involved in medicinal chemistry  
 Medicinal chemistry covers following three steps: 
A discovery step, consisting of the choice of the therapeutic target (receptor, 
enzyme, transport group, cellular or in vivo model) and the identification (or discovery) 
and production of new active substances interacting with the selected target. Such 
compounds are usually called lead compounds; they can originate from synthetic organic 
chemistry, from natural sources or from biotechnological processes. 
An optimization step, that deals with the improvement of the lead structure. The 
optimization process takes primarily into account the increase in potency, selectivity and 
toxicity. Its characteristics are the establishment and analysis of structure activity 
relationships, to enable the understanding of the molecular mode of action. However, an 
assessment of the pharmacokinetic parameters (ADME) and oral bioavailability is almost 
systematically practiced at an early stage of the development. 
A development step is the continuation of the improvement of the 
pharmacokinetic and pharmaceutical properties (chemical formulation) of the active 
substances in order to render them suitable for clinical use. This chemical formulation 
process can consist in the preparation of better absorbed compounds of sustained release 
formulations of water-soluble derivatives or in the elimination of properties related to the 
patient’s compliance  
Molecular and cellular pharmacology 
This is the study of pharmacological action of drug at the molecular or at the 
cellular level. The first objective is to identify the cellular levels of action. Three levels, 
important for drug activity can be distinguished:  
The plastic membrane which is very rich in potential targets, notably in receptors. 
The cytosol with its enzymatic equipment and the organelle membranes with their 
particular ion transporters. The nucleus which notably responds to the steroid hormones 
to anti cancer drugs and to gene therapy. 
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Systemic pharmacology 
 The systemic pharmacology considers the effects of biologically active substances 
in integrated systems (cardiovascular, skeletal, central nervous, gastrointestinal, 
pulmonary, etc.). The experimentation is performed in intact animals or in isolated organs 
(isolated heart, isolated arteria, perfused kidney, etc.).  
The main difficulty resides in the design of animal experimental models that are 
predictive of an activity in a human disease. As many pharmacological experiments are 
still performed on healthy animals or on disease-stimulating paradigms, their 
extrapolation to clinical situations is questionable.  
The availability of transgenic mice, in which the genes of a human disease were 
introduced, represents an interesting progress. However in all animal models, intra and 
interspecific physiological variations account for rather imprecise results the margins 
being often as elevated as +/- 50 %. 
Clinical pharmacology 
 Clinical pharmacology deals with the examination in humans of the effects of a 
new drug candidate. The tests are performed under the responsibility of the clinical 
pharmacologist who is generally a medical doctor and who has to report to an ethical 
committee.  
Phase I tests take place in healthy volunteers. They aim to assess the level of 
dosing and tolerance (dose ranging) and to initiate metabolic studies in humans. Once the 
safety margin has been determined phase II, II and IV studies examine successively the 
beneficial effects in patients the possible side-effect, the comparison of the drug with 
reference drugs and the emergence of new therapeutic indications.  
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CLASSIFICATION SYSTEMS OF MEDICINES 
All attempts to establish clear-cut and well-balanced drug classifications lead to 
failures, due to the complex nature of the medicaments, which do not fit into simplified 
systems. The best way to illustrate how drugs are situated with regard to each other is to 
use several classification systems, based on different criteria. 
A. Theoretical classification 
Based on the origin of the drug 
 Drug from natural origin can come from three sources. They can originate from 
minerals. Various simple inorganic substances are still in use in medicine: sulphur, 
iodine, phosphates and arsenates, calcium, sodium, magnesium, iron and bismuth salts 
etc. From the animal kingdom some hormones (e.g. insulin) and fish liver oils (vitamin A 
and E) were extracted for a long time. Biliary salts yield precursors for steroid hemi 
synthesis (corticoids, sexual hormones). However, the majority of natural compounds are 
produced by vegetals (alkaloids, cardiac glycosides, antibiotics, anti cancer drugs). 
Drugs from synthetic origin relay the natural compounds in providing improved 
and or simplified synthetic analogues the production of which are not dependent on 
hazardous agricultural supplies. 
In an intermediary position between natural and synthetic compounds are found 
the various fermentation products (vitamins, amino acids) and the products issued from 
genetic engineering (e.g. recombinant insulin). 
Based on the mode of action 
One can distinguish between medicaments which really treat the cause of the   
disease, medicaments which compensate for the deficiency of a given substance and 
medicaments which only aim to alleviate the symptoms of the disease. 
The drugs acting on the casual agent of the disease are called etiological drugs 
and represent ‘true’ medicaments. Presently most of them belong to the class of 
chimiotherapeutic drugs, i.e. to compounds used to treat infections (antibacterial and 
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antiviral) and parasitic diseases. The principle of their activity resides in their selective 
toxicity: destroy the invader without destroying the host. 
Logically can be added to this group a certain number of drugs used by healthy 
persons in a preventive way in order to protect them from a future illness 
(vaccinotherapy, aspirin and anticoagulants to prevent cardiac infarcts, vitamins and 
antioxidants against neurodegenerative disorders). Other drugs can temporarily modify a 
physiological process (steroidal contraceptives). 
Substitutive drugs take the place of a missing substance: the lack can be due to 
dietary reasons (vitamin deficiency) or to a physiological disturbance (insulin in diabetes, 
estrogens in menopause). The substitutive treatment can cover a very short period 
(intravenous rehydration in case of hemorrhages and diarrhea), or can last the whole life 
(hormonal treatment in Addison’s disease). 
Symptomatic treatments are given in order to attenuate or to neutralize the 
disorders which result from a pathological state. They abolish general symptoms such as 
fever, pain or insomnia. However, their activity can be much more specific and targeted 
to a particular system: thus symptomatic drugs are available for cardiovascular for 
neuropsychiatric for respiratory for digestive diseases etc. As a rule, a symptomatic 
treatment is not supposed to cure the patient, but rather to render his all-day life more 
comfortable and to prolong his life. Antihypertensive drugs for example abolish, or at 
leaset diminish, the symptoms associated with arterial hypertension, but they play also a 
preventive role against the cardio-vascular complications of hypertension (notably 
myocardial infarct). 
Based on the nature of the illness 
 The so-called physiological classification was adopted by the World Health 
Organization (WHO) in 1968. It classifies the drugs according to the body system on 
which they act (drugs affecting the central nervous system, the gastro-urinary tract, the 
musculoskeletal system, for example).  
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Based on the chemical structure  
 This classification is important to people involved in pharmaceutical research. An 
expert in peptide or prostaglandin chemistry will be primarily concerned with the various 
chemical manipulations that can be performed on these molecules and will rely on 
someone else to screen them for effects against the various illnesses susceptible to 
peptide or prostaglandin therapy. On the other hand, the chemical classification allows an 
excellent overview of all the congeners and analogues derived from an initial lead and 
thus facilitate structure-activity considerations. 
B. Practical classification 
 In practice the most powerful and useful system developed so far is a compromise 
between the methods, known as the anatomical-therapeutic-chemical system (ATC). The 
system divides products in to 13 general groups according to the body system on which 
they act: A, alimentary system: B, blood and blood-forming organs, and so on. This is the 
usually followed by the name of the disease they cure and finally by a description of the 
chemical classes involved. 
 An even simpler classification is usual among the medicinal chemist community, 
if distinguishes between four major classes of drugs: 
Agents acting on the central nervous system: Psychotropic and neurological drugs 
 In man, the central nervous system (CNS) comprises the brain and the spinal cord 
and it controls the thoughts, emotions, sensations and motor functions.  
 The psychotropic drugs such as  
 Antidepressants,  
 Antipsychotics,  
 Anxiolytics  
 Psychomimetics  
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The neurological drugs such as:  
 Anticonvulsants  
 Sedatives and hypnotics  
 Analgesics  
 Anti-parkinsonian drugs, etc. 
Pharmacodynamic agents 
 The pharmocodynamic agents are drugs affecting the normal dynamic processes 
of the body and particularly the cardio-vascular domain. This group is composed of the 
anti-arrythmics, the anti-anginals, the vasodilators, the anti-hypertensives, the diuretics 
and the anti-thrombotics which all, directly or indirectly, concern the heart or the blood 
circulation. Traditional the anti-allergic drugs and the drugs acting on the gastrointestinal 
tract are also included in the class of pharmocodynamic agents. 
Chemotherapeutic agents 
 Initially, the term chemotherapy referred to the treatment by means of drugs 
preventing selectivity the development of various kinds of infesting hosts: protozoa 
(amoebas, leishmania, hematozoa, treponema, trypanosoma), microbes, viruses and as 
rule all parasites which propagate infectious diseases. IN the same context of selective 
toxicity, the anti-cancer treatments also belong to the class of chemotherapeutic agents. 
Agents acting on metabolic diseases and endocrine functions 
 This category of drugs is made up of a collection of agents which do not easily fit 
in the previous classes. It consists of the anti-inflammatory, the anti-arthritics, the anti-
diabetics, and the hypolipidemic agents, the anorectics and most of the peptide and 
steroidal hormones.  
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INTRODUCTION [1-8] 
 The discipline of medicinal chemistry is committed to the discovery and 
development of new agents for treating diseases. Most of this activity is directed to new 
natural or synthetic organic compounds.  
Inorganic compounds continue to be important in therapy, e.g., trace elements in 
nutritional therapy, antacids and radiopharmaceuticals but organic molecules with 
increasingly specific pharmacological activities are clearly dominant.  
Development of organic compounds has grown beyond traditional synthetic 
methods. It now includes the exciting new field of biotechnology using the cell’s 
biochemistry to synthesize new compounds.  
Techniques ranging from recombinant DNA and site-directed mutagenesis to 
fusion of cell lines have greatly broadened the possibilities for new entities.  
Medicinal chemistry 
 Medicinal chemistry concerns the discovery, the development, the identification 
and the interpretation of the mode of action of biologically active compounds at the 
molecular level. But the interest of the medicinal chemistry is also concerned with the 
study, identification and synthesis of the metabolic products of drugs and related 
compounds. 
Developments and discoveries in medicinal chemistry 
The pharmacist now dispenses modified human insulin’s that provide more 
convenient dosing schedules, cell-stimulating factors that have changed the dosing 
regimens for chemotherapy, humanized monoclonal antibodies that target specific tissues 
and fused receptors that intercept immune cell-generated cytokines. 
 The process of establishing a new pharmaceutical is very difficult and involves 
the talents of people from variety of disciplines, including chemistry, biochemistry, 
molecular biology, physiology, pharmacology, pharmaceutics and medicine.  
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Medicinal chemistry itself is concerned mainly with the organic, analytical and 
biochemical aspects of this process but the chemist must interact productively with those 
in other disciplines. Thus, medicinal chemistry occupies a strategic position at the 
interface of chemistry and biology.  
 The earliest drug discoveries were made by random sampling of higher plants. 
Some of this sampling, although based on anecdotal evidence, led to the use of such 
crude plant drugs as opium, belladonna and ephedrine that have been important for 
centuries.  
With the accidental discovery of penicillin came the screening of microorganisms 
and the large number of antibiotics from bacterial and fungal sources. Many of these 
antibiotics provided the prototypical structure that the medicinal chemist modified to 
obtain anti-bacterial drugs with better therapeutic profiles. With the changes in federal 
legislation reducing the efficacy requirement for “nutriceutical” the public increasingly is 
using so-called nontraditional or alternative medicinal that are sold over the counter, 
many outside of traditional pharmacy distribution channels.  
 Hundreds of thousands of new organic chemicals are prepared annually 
throughout the world and many of them are entered in to pharmacological screens to 
determine whether they have useful biological activity. This process of random screening 
has been considered inefficient, but it has resulted in the identification of new lead 
compounds whose structures have been optimized to produce clinical agents. Sometimes, 
a lead develops by careful observation of the pharmacological behavior of an existing 
drug.  
The discovery that amantadine protects and treats early influenza A came from a 
general screen for antiviral agents. The use of amantadine in long-term care facilities 
showed that it also could be used to treat parkinsonian disorders. More recently, 
automated high-throughput screening systems utilizing cell culture systems with linked 
enzyme assays and receptor molecules derived from gene cloning have greatly increased 
the efficiency of random screening. It is now practical to screen enormous libraries of 
peptides and nucleic acids obtained from combinatorial chemistry procedures. 
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Molecular design with target tissue   
Rational design, the opposite approach to high-volume screening, is also 
flourishing. Significant advances in x-ray crystallography and nuclear magnetic 
resonance have made it possible to obtain detailed representations of enzymes and other 
drug receptors.  
The techniques of molecular graphics and computational chemistry have provided 
novel chemical structures that have led to new drugs with potent medicinal activities. 
Development of HIV protease inhibitors and angiotensin-converting enzyme (ACE) 
inhibitors came from an understanding of the geometry and chemical character of the 
respective enzyme’s active site.  
Even if the receptor structure is not known in detail, rational approaches based on 
the physiochemical properties of lead compounds can provide new drugs. For example, 
the development of cimetidine as an antinuclear drug involved a careful study of the 
changes in antagonism of H2-histamine receptors induced by varying the physical 
properties of structures. 
Medicinal chemistry is an interdisciplinary science covering a particularly wide 
domain situated at the interface of organic chemistry with life sciences such as 
biochemistry, pharmacology, molecular biology, immunology, pharmacokinetics and 
toxicology on one side and chemistry based disciplines such as physical chemistry, 
crystallography, spectroscopy and computer based information technologies on the other. 
The knowledge of the molecular targets (enzymes, receptors, nucleic acids) has 
benefitted from the progress made in molecular biology, genetic engineering and 
structural biology. For an increasing number of targets the three dimensional structure 
and the precise location of the active site are known.  
The design of new active substances is therefore more and more based on results 
obtained from ligand-receptor modeling studies. One can actually consider the existence 
of a molecular pharmacochemistry making a pair with molecular pharmacology. 
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Principles of medicinal chemistry 
 To provide an understanding of the principles of medicinal chemistry, it is 
necessary to consider the physiochemical properties used to develop new 
pharmacologically active compounds and their mechanism of action, the drug’s 
metabolism including possible biological activities of the metabolites, the importance of 
stereochemistry in drug design, and the methods used to determine what “ space “ a drug 
occupies. 
It is important for the pharmacist and the public to understand the rigor that is 
required for prescription only and FDA approved nonprescription products to be 
approved relative to the nontraditional products.  
It also is important for all people in the health care field and the public to realize 
that whether these nontraditional products are effective as claimed or not many of the 
alternate medicines contain pharmacologically active agents that can potentiate or 
interfere with physician prescribed therapy.  
Objective of medicinal chemistry 
 The objective of medicinal chemistry is design and production of compounds that 
can be used in medicine for the prevention, treatment and cure of human or animal 
disease. Thus medicinal chemistry is a part of pharmacology, this latter being taken in its 
etymological sense. 
 Medicinal chemistry also includes the study of already existing drugs, of their 
pharmacological properties and their structure activity relationships. An official 
definition of medicinal chemistry was given by an IUPAC specialized commission. 
A certain number of terms more or less synonymous with medicinal chemistry are 
used: pharmacochemistry, molecular pharmacochemistry, drug design and selective 
toxicity. The French equivalent to medicinal chemistry is ‘Chimie Therapeutique’ and the 
german one is ‘Arzneimittelforschung’ 
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Steps involved in medicinal chemistry  
 Medicinal chemistry covers following three steps: 
A discovery step, consisting of the choice of the therapeutic target (receptor, 
enzyme, transport group, cellular or in vivo model) and the identification (or discovery) 
and production of new active substances interacting with the selected target. Such 
compounds are usually called lead compounds; they can originate from synthetic organic 
chemistry, from natural sources or from biotechnological processes. 
An optimization step, that deals with the improvement of the lead structure. The 
optimization process takes primarily into account the increase in potency, selectivity and 
toxicity. Its characteristics are the establishment and analysis of structure activity 
relationships, to enable the understanding of the molecular mode of action. However, an 
assessment of the pharmacokinetic parameters (ADME) and oral bioavailability is almost 
systematically practiced at an early stage of the development. 
A development step is the continuation of the improvement of the 
pharmacokinetic and pharmaceutical properties (chemical formulation) of the active 
substances in order to render them suitable for clinical use. This chemical formulation 
process can consist in the preparation of better absorbed compounds of sustained release 
formulations of water-soluble derivatives or in the elimination of properties related to the 
patient’s compliance  
Molecular and cellular pharmacology 
This is the study of pharmacological action of drug at the molecular or at the 
cellular level. The first objective is to identify the cellular levels of action. Three levels, 
important for drug activity can be distinguished:  
The plastic membrane which is very rich in potential targets, notably in receptors. 
The cytosol with its enzymatic equipment and the organelle membranes with their 
particular ion transporters. The nucleus which notably responds to the steroid hormones 
to anti cancer drugs and to gene therapy. 
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Systemic pharmacology 
 The systemic pharmacology considers the effects of biologically active substances 
in integrated systems (cardiovascular, skeletal, central nervous, gastrointestinal, 
pulmonary, etc.). The experimentation is performed in intact animals or in isolated organs 
(isolated heart, isolated arteria, perfused kidney, etc.).  
The main difficulty resides in the design of animal experimental models that are 
predictive of an activity in a human disease. As many pharmacological experiments are 
still performed on healthy animals or on disease-stimulating paradigms, their 
extrapolation to clinical situations is questionable.  
The availability of transgenic mice, in which the genes of a human disease were 
introduced, represents an interesting progress. However in all animal models, intra and 
interspecific physiological variations account for rather imprecise results the margins 
being often as elevated as +/- 50 %. 
Clinical pharmacology 
 Clinical pharmacology deals with the examination in humans of the effects of a 
new drug candidate. The tests are performed under the responsibility of the clinical 
pharmacologist who is generally a medical doctor and who has to report to an ethical 
committee.  
Phase I tests take place in healthy volunteers. They aim to assess the level of 
dosing and tolerance (dose ranging) and to initiate metabolic studies in humans. Once the 
safety margin has been determined phase II, II and IV studies examine successively the 
beneficial effects in patients the possible side-effect, the comparison of the drug with 
reference drugs and the emergence of new therapeutic indications.  
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CLASSIFICATION SYSTEMS OF MEDICINES 
All attempts to establish clear-cut and well-balanced drug classifications lead to 
failures, due to the complex nature of the medicaments, which do not fit into simplified 
systems. The best way to illustrate how drugs are situated with regard to each other is to 
use several classification systems, based on different criteria. 
A. Theoretical classification 
Based on the origin of the drug 
 Drug from natural origin can come from three sources. They can originate from 
minerals. Various simple inorganic substances are still in use in medicine: sulphur, 
iodine, phosphates and arsenates, calcium, sodium, magnesium, iron and bismuth salts 
etc. From the animal kingdom some hormones (e.g. insulin) and fish liver oils (vitamin A 
and E) were extracted for a long time. Biliary salts yield precursors for steroid hemi 
synthesis (corticoids, sexual hormones). However, the majority of natural compounds are 
produced by vegetals (alkaloids, cardiac glycosides, antibiotics, anti cancer drugs). 
Drugs from synthetic origin relay the natural compounds in providing improved 
and or simplified synthetic analogues the production of which are not dependent on 
hazardous agricultural supplies. 
In an intermediary position between natural and synthetic compounds are found 
the various fermentation products (vitamins, amino acids) and the products issued from 
genetic engineering (e.g. recombinant insulin). 
Based on the mode of action 
One can distinguish between medicaments which really treat the cause of the   
disease, medicaments which compensate for the deficiency of a given substance and 
medicaments which only aim to alleviate the symptoms of the disease. 
The drugs acting on the casual agent of the disease are called etiological drugs 
and represent ‘true’ medicaments. Presently most of them belong to the class of 
chimiotherapeutic drugs, i.e. to compounds used to treat infections (antibacterial and 
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antiviral) and parasitic diseases. The principle of their activity resides in their selective 
toxicity: destroy the invader without destroying the host. 
Logically can be added to this group a certain number of drugs used by healthy 
persons in a preventive way in order to protect them from a future illness 
(vaccinotherapy, aspirin and anticoagulants to prevent cardiac infarcts, vitamins and 
antioxidants against neurodegenerative disorders). Other drugs can temporarily modify a 
physiological process (steroidal contraceptives). 
Substitutive drugs take the place of a missing substance: the lack can be due to 
dietary reasons (vitamin deficiency) or to a physiological disturbance (insulin in diabetes, 
estrogens in menopause). The substitutive treatment can cover a very short period 
(intravenous rehydration in case of hemorrhages and diarrhea), or can last the whole life 
(hormonal treatment in Addison’s disease). 
Symptomatic treatments are given in order to attenuate or to neutralize the 
disorders which result from a pathological state. They abolish general symptoms such as 
fever, pain or insomnia. However, their activity can be much more specific and targeted 
to a particular system: thus symptomatic drugs are available for cardiovascular for 
neuropsychiatric for respiratory for digestive diseases etc. As a rule, a symptomatic 
treatment is not supposed to cure the patient, but rather to render his all-day life more 
comfortable and to prolong his life. Antihypertensive drugs for example abolish, or at 
leaset diminish, the symptoms associated with arterial hypertension, but they play also a 
preventive role against the cardio-vascular complications of hypertension (notably 
myocardial infarct). 
Based on the nature of the illness 
 The so-called physiological classification was adopted by the World Health 
Organization (WHO) in 1968. It classifies the drugs according to the body system on 
which they act (drugs affecting the central nervous system, the gastro-urinary tract, the 
musculoskeletal system, for example).  
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Based on the chemical structure  
 This classification is important to people involved in pharmaceutical research. An 
expert in peptide or prostaglandin chemistry will be primarily concerned with the various 
chemical manipulations that can be performed on these molecules and will rely on 
someone else to screen them for effects against the various illnesses susceptible to 
peptide or prostaglandin therapy. On the other hand, the chemical classification allows an 
excellent overview of all the congeners and analogues derived from an initial lead and 
thus facilitate structure-activity considerations. 
B. Practical classification 
 In practice the most powerful and useful system developed so far is a compromise 
between the methods, known as the anatomical-therapeutic-chemical system (ATC). The 
system divides products in to 13 general groups according to the body system on which 
they act: A, alimentary system: B, blood and blood-forming organs, and so on. This is the 
usually followed by the name of the disease they cure and finally by a description of the 
chemical classes involved. 
 An even simpler classification is usual among the medicinal chemist community, 
if distinguishes between four major classes of drugs: 
Agents acting on the central nervous system: Psychotropic and neurological drugs 
 In man, the central nervous system (CNS) comprises the brain and the spinal cord 
and it controls the thoughts, emotions, sensations and motor functions.  
 The psychotropic drugs such as  
 Antidepressants,  
 Antipsychotics,  
 Anxiolytics  
 Psychomimetics  
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The neurological drugs such as:  
 Anticonvulsants  
 Sedatives and hypnotics  
 Analgesics  
 Anti-parkinsonian drugs, etc. 
Pharmacodynamic agents 
 The pharmocodynamic agents are drugs affecting the normal dynamic processes 
of the body and particularly the cardio-vascular domain. This group is composed of the 
anti-arrythmics, the anti-anginals, the vasodilators, the anti-hypertensives, the diuretics 
and the anti-thrombotics which all, directly or indirectly, concern the heart or the blood 
circulation. Traditional the anti-allergic drugs and the drugs acting on the gastrointestinal 
tract are also included in the class of pharmocodynamic agents. 
Chemotherapeutic agents 
 Initially, the term chemotherapy referred to the treatment by means of drugs 
preventing selectivity the development of various kinds of infesting hosts: protozoa 
(amoebas, leishmania, hematozoa, treponema, trypanosoma), microbes, viruses and as 
rule all parasites which propagate infectious diseases. IN the same context of selective 
toxicity, the anti-cancer treatments also belong to the class of chemotherapeutic agents. 
Agents acting on metabolic diseases and endocrine functions 
 This category of drugs is made up of a collection of agents which do not easily fit 
in the previous classes. It consists of the anti-inflammatory, the anti-arthritics, the anti-
diabetics, and the hypolipidemic agents, the anorectics and most of the peptide and 
steroidal hormones.  
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LITERATURE REVIEW [9-38] 
 
COUMARIN DERIVATIVES 
♣ K. B. Vyas et al. [9] [2009] have synthesised metal complexes of 3-[ {-(3’,4’-
di methoxy phenyl) }-prop-2-enoyl]-4-hydroxy-6-methyl-2H-chromene-2-one 
with Cu(II), Ni(II), Fe(II), Co(II) and Mn(II) which have been characterized 
using elemental analysis, IR spectra and conductivity measurements. These 
studies revealed that they are having octahedral geometry of the type [ML2 
(H2O)2 ]. In vitro antimicrobial activity of all synthesized compounds and 
standard drugs have been evaluated against four strains of bacterial culture and 
one fungus, which includes two gram +ve bacterial culture and two gram -ve 
bacteria culture. The compounds show net enhancement in activity on 
coordination of metals with ligand but moderate activity as compared to 
standard drugs. 
O O
CH3
O O
Mt
+
R
 
 
♣ P. Selvam et al. [10] [2010] have new synthesized new series of coumarin 
derivatives by condensation of ethyl acetoacetate and resorcinol. The chemical 
structures of the synthesized compounds were confirmed by means of IR, 1H-
NMR and Mass spectral analysis. These compounds were screened for their 
Antioxidant, Analgesic and Anti-inflammatory activities. 
 
O O
NH
R
X
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♣ Parameswaran Manojkumar et al. [11] [2009] have synthesized coumarinyl 
heterocycles elucidate the potential role of these compounds as antioxidants 
and cytotoxic agents against Dalton’s lymphoma ascites tumour cells (DLA) 
and Ehrlich ascites carcinoma cells (EAC). The synthesis of coumarin 
derivatives containing pyrazole, pyrazolone, thiazolidin-4-one, 5-
carboxymethyl-4-thiazolidinone and 3-acetyl-1,3,4-oxadiazole ring is 
reported. 4-Methylcoumarinyl- 7-oxyacetic acid hydrazide (1) reacted with 
arylazopropanes or hydrazono-3-oxobutyrate derivatives to form pyrazole (3a-
c) and pyrazolone derivatives (5a-c). Heterocyclisation of Schiff’s bases of 1 
with thioglycolic acid, thiomalic acid or acetic anhydride afforded novel 
heterocyclic derivatives 4-thiazolidinones (7a-c), 5-carboxymethyl- 4-
thiazolidinones (8a-c) and oxadiazoles (9a-c), respectively. Some of the 
compounds showed promising antioxidant activity in vitro and cytotoxic 
activity against DLA cells and EAC cells.  
 
♣ Shaabani et al. [12] [2009] have synthesized coumarin derivatives in relatively 
high yields via Knoevenagel condensation reaction of an orthohydroxyaryl 
aldehyde and an activated β-dicarbonyl C-H acid in the presence of a 
recyclable ionic liquid 1,1,3,3-N,N,N',N'- tetramethylguanidinium 
trifluoroacetate under either classical heating conditions or using microwave 
irradiation. Application of microwave irradiation decreased the required time 
by a factor of about 200. The ionic liquid could be recycled several times 
without loss of efficiency with regards to the reaction times and yields. 
O O
COOH
X  
 
♣ Hosanagara N. Harishkumar et al. [13] [2011] have studied the influence of 
choline chloride/urea ionic liquid in solid phase on the Knoevenagel 
condensation. The active methylene compounds such as meldrum’s acid, 
diethylmalonate, ethyl cyanoacetate, dimethylmalonate, were efficiently 
condensed with various salicylaldehydes in presence of choline chloride/urea 
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ionic liquid without using any solvents or additional catalyst. The reaction is 
remarkably facile because of the air and water stability of the catalyst, and 
needs no special precautions. The reactions were completed within 1hr with 
excellent yields (95%). The products formed were sufficiently pure, and can 
be easily recovered. The use of ionic liquid choline chloride/urea in solid 
phase offered several significant advantages such as low cost, greater 
selectivity and easy isolation of products. 
O O
CH3
R2
R1
R3
 
 
♣ Afsheen Arshad et al. [14] [2011] have synthesized two novel series of 
hydrazinyl thiazolyl coumarin derivatives and fully characterized by IR, 1H 
NMR, 13C NMR, elemental analysis and mass spectral data. The structures of 
some compounds were further confirmed by X-ray crystallography. All of 
these derivatives, 10aed and 15aeh, were screened in vitro for antimicrobial 
activity against various bacteria species including Mycobacterium tuberculosis 
and Candida albicans. The compounds 10c, 10d and 15e exhibited very good 
activities against all of the tested microbial strains. 
O O
R
 
 
♣ Koneni V. Sashidhara et al. [15] [2010] have synthesized a series of novel 
coumarin bisindole heterocycles by following an uncommon method and 
evaluated for their antihyperlipidemic activity in hyperlipidemic hamster 
model. Among 12 compounds tested, the compound 5e showed potent 
antihyperlipidemic activity and was found to decrease the plasma triglyceride 
levels (TG) by 55%, total cholesterol (TC) by 20%, accompanied by an 
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increase in HDL-C/TC ratio by 42% in hyperlipidemic rats to a greater degree 
than some of the reference statins. 
O
O
O
O
R
N
R1
R2
NR1
R2  
 
♣ Andrea Behrenswertha et al. [16] [2009] have synthesized 36 coumarin and 
2H-chromene derivatives by applying a recently developed umpoled domino 
reaction using substituted salicylaldehyde and α,β-unsaturated aldehyde 
derivatives as starting compounds. In radioligand binding studies 5-substituted 
3-benzylcoumarin derivatives showed affinity to cannabinoid CB1 and CB2 
receptors and were identified as new lead structures. In further GTPγS binding 
studies selected compounds were shown to be antagonists or inverse agonists. 
O O
R5
R1
R2
R3
R4
 
 
♣ Hakkı Murat Bilgina et al. [17] [2009] have evaluated the possible 
cytoprotective properties of coumarin and some coumarin derivatives against 
CCl4 (carbon tetrachloride)-induced hepatotoxicity. Coumarin (1,2-
benzopyrone) and coumarin derivatives esculetin (6,7-dihydroxycoumarin), 
scoparone (6,7-dimethoxycoumarin) and 4-methylumbelliferone (7-hyroxy-4-
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methyl) were examined for their protective effect against CCl4-induced 
hepatotoxicity in Male Sprague-Dawley rats. A single toxic dose of CCl4 (1.25 
ml kg−1, orally) produced liver damage in rats, seen histologically as 
centrilobular necrosis. Administration of CCl4 increased serum enzyme levels 
of aspartate transaminase (AST), alanine transaminase (ALT), and alkaline 
phosphatase (ALP). Pre-treatment of rats with esculetin (31.15 mg kg−1, 
orally) and scoparone (35 mg kg−1, orally) significantly prevented CCl4-
induced increase in serum enzymes, whereas 4-methylumbelliferone (35 mg 
kg−1) and  coumarin  (30 mg kg−1) had no effect against CCl4-induced rise in 
serum enzymes. Morphological findings were consistent with the plasma 
transaminase observations. Among the coumarin analogs, esculetin, which 
possesses orthodihydroxy coumarins, showed the strongest protective effect 
against CCl4-induced liver damage, followed by scoparone, 4-
methylumbelliferone and coumarin, respectively. The results of this study 
indicate that the chemical structures of coumarins play an important role in the 
prevention of liver toxicity. 
O OR1
R2
R3
 
 
♣ Tianzhi Yua et al. [18] [2009] have synthesized two new coumarin derivatives, 
7-(diethylamino)-3-(pyridin-2-yl) coumarin (DAPC) and 3-(pyridin-2-yl)-
benzo[5,6] coumarin  (PBC), and characterized by elemental analysis, 1H 
NMR, FT-IR and UV–visible absorption spectra. Their structures were 
determined by X-ray crystallography single crystal analysis. The fluorescence 
behaviours of the compounds in dichloromethane solutions were observed. 
The results show that the compound DAPC exhibits high fluorescence 
quantum yield (0.84) and they exhibit strong blue emissions under ultraviolet 
light excitation. The energy levels of the HOMO and LUMO of the 
compounds have been calculated with density functional theory (DFT) and 
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time-dependent density functional theory (TD-DFT) at B3LYP/6-31G(d) 
level. 
O O
N
N
CH3
CH3
    
O
O
N
 
(DAPC)                                (PBC) 
 
♣ Kinza Aslam et al. [19] [2010] have coumarin synthesized by Perkin reaction 
using salicylaldehyde, acetic acid and sodium acetate. Due to the misuse of 
acetic anhydride in narcotics synthesis, acetic acid was substituted for acetic 
anhydride in Perkin reaction. On the basis of this substitution a hypothesis was 
proposed that “acetic acid could be substituted as an acetylating agent in place 
of acetic anhydride in coumarin synthesis via Perkin reaction". In the present 
research project, salicylaldehyde was prepared from phenol, sodium hydroxide 
and chloroform for further procedure. Then four different coumarin samples 
were synthesized by changing the parameter of reactants proportions. From 
this parameter, we designed a trend of high product yield. Yields of Coumarin 
samples will lead towards either acception or rejection of the above proposed 
hypothesis. In the next step, these Coumarin samples were characterized by 
age yield (%), solubility and melting points. At last Antibacterial activities of 
all the four coumarin samples were evaluated against two bacterial strains; 
E.coli and S.aureus. As a consequence of all above, it was inferred that the 
yields of all coumarin samples obtained were low as compared to the yield 
obtained by the use of acetic anhydride in previous reports. This led to the 
rejection of proposed hypothesis. Among four Coumarin samples, sample-4 
obtained by taking equal amounts of all the reactants had shown maximum 
yield, best characterization and excellent antibacterial activity. In spite of low 
yields obtained, the remarkable antibacterial activities of Coumarin samples 
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have enabled us to suggest coumarin as a strong antibacterial agent and it must 
be employed for further applications. 
O O  
 
♣ Hassan Valizadeh et al. [20] [2005] have described the ability of titanium (IV) 
chloride as a catalyst to promote the Pechmann condensation reaction with a 
range of phenols and β-keto esters. The reaction was carried out by addition of 
TiCl4 to a mixture of the phenol and the β-keto ester with thorough stirring in 
the absence of a solvent and represents an improvement on the classical 
Pechmann conditions. The yields of coumarins obtained via this novel 
protocol were significantly higher than those using the conventional method 
and the reaction duration was reduced to a few minutes or even a few seconds. 
O O
R2
R1     
O O
CH3
 
 
♣ Rangappa S. Keri et al. [21] [2009] have used Phosphotungstic acid (PTA) as 
an efficient catalyst for the von Pechmann condensation reaction of phenols 
and b-keto esters to synthesize coumarin under solvent-free conditions. This 
method was compared with those of the reactions in the different solvents and 
catalysts. The methodology presented offers significant improvements for the 
synthesis of coumarins with regard to yield of products, simplicity in operation 
and green aspects by avoiding toxic conventional catalysts and solvents. 
O O
CH 3R 4
R 3
R 2
R 1  
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♣ Jae-Chul Jung et al. [22] [2009] have reviewed to summarize recent chemical 
syntheses and structural modifications of 4-hydroxycoumarin and its 
derivatives, of interest due to their characteristic conjugated molecular 
architecture and biological activities. 
X O
R
OH
X=N & S
 
 
♣ Stojadin V. Dekić et al. [23] [2007] have studied the reactions of 4-chloro-2-
oxo-2H-chromene-3-carbonitrile (1) with 4-methylpyridin- 2-ylamine (2) and 
6-methoxy-benzothiazol-2-ylamine (3) in acetonitrile containing a catalytic 
amount of triethylamine which gave the new coumarin derivatives 7-imino-
10-methyl-7H- 5-oxa-7a,12-diaza-benzo[a]anthracen-6-one (4) and 7-imino-
10-methoxy-7H-5-oxa-12- thia-7a,13-diaza-indeno[1,2-b]phenanthren-6-one 
(5) in 52 and 39% yields, respectively. The novel compounds were subjected 
to acid hydrolysis giving the corresponding oxoderivatives 10-methyl-5-oxa-
7a,12-diaza-benzo[a]anthracene-6,7-dione (6) and 10- methoxy-5-oxa-12-thia-
7a,13-diaza-indeno[1,2-b]phenanthrene-6,7-dione (7) in 64 and 58% yields, 
respectively. The structural assignments of the synthesized compounds were 
based on elemental analyses, IR and proton NMR spectra. 
O O
NN
R
    O O
NN
R
S
CH3
 
R= O, NH    R= O, NH 
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INDOLE DERVIVATIVES 
♣ Feng Ping Yi et al. [24] [2007] have performed Fischer indole cyclization of 
phenyl hydrazine and various ketones using carboxyl-functionalized ionic 
liquid, 1-carboxymethyl- 3-methylimidazolium tetra fluoro borate (abbreviated 
as [cmmim][BF4]) as catalyst. The yields of the target compounds were 80–
92%, the purities were 96–98%. The catalyst could be recovered and reused 
for at least six times without significant loss in activity. 
N
H
R'
R
 
 
♣ Huseyin Cavdar et al. [25] [2005] have done regioselective alkylation at the 2-
position of the indole nucleus by treating indole with 4,7-Dihydroindole 
through conjugate addition with a, β-unsaturated carbonyl compounds. The 
oxidation of the Michael adducts affords the corresponding 2-substituted 
indole derivatives which were characterized by spectroscopic methods. 
N
H
R
 
 
♣ Mohamed A. A. Radwan et al. [26] [2007] Treated 3-cyanoacetyl indole (1) 
with the diazonium salts of 3-phenyl-5-aminopyrazole and 2-
aminobenzimidazole afforded the corresponding hydrazones (4) and (5). 3-
Cyanoacetyl indole reacted with phenylisothiocyanate to give the 
corresponding thioacetanilide derivative (7). Treatment of (7) with 
hydrazonoyl chlorides afforded the corresponding 1,3,4-thiadiazole derivatives 
(8a–f) and (9). Also, the thioacetanilide reacted with a-haloketones to afford 
thiophene derivatives (10a,b) (tenidap analogues), or thiazolidin-4-one 
K.M.College of Pharmacy                                                                                 LITERATURE REVIEW 
 
Dept. of Pharmaceutical Chemistry Page 20 
 
derivative (11). The newly synthesized compounds were found to possess 
potential anti-inflammatory and analgesic activities. 
N
H
R
 
 
♣ Yuichi Sugimoto et al. [27] [2006] have discovered A novel series of 2-(1,2,4-
oxadiazol-5-yl)-1H-indole derivatives as nociceptin/orphanin FQ (N/OFQ) 
receptor antagonists. Systematic modification of our original lead by changing 
the pendant functional groups, linker, heterocyclic core, and basic side chain 
revealed the structure–activity requirements for this novel template and 
resulted in the identification of more potent analog with improved potency as 
compared to the parent compound. 
N
H
R
R'
 
  
♣ A Leonardi et al [28] [1994] have done synthesis and pharmacological 
evaluation of a series of pyrrolidine analogues of thymoxamine allowed access 
to the basic SAR for the aromatic substitution pattern. Their results confirmed 
the relevance of the simultaneous presence of the hydroxy and methyl groups 
on the benzene ring and prompted to prepare the corresponding indole 
congener. The principle of the phenol-indol bioisosterism was confirmed by 
the results obtained. The introduction of the N-(2-methoxyphenyl) piperazine 
moiety instead of pyrrolidine changed the receptor affinity profile and 
introduced a good uroselectivity. 
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♣ Mukund Jha et al. [29] [2011] have developed the one-pot triacetylation of 
indolin-3-ones. They have devised a simple two-step reaction sequences to 
produce di- and mono-acetylated indoles from indolin-2-ones. The indolin-2-
ones were first subjected to acetylation in the presence of acetic anhydride and 
a catalytic amount of N,N-dimethyl amino pyridine to give 2-acetoxy-1,3-
diacetylindoles. Subsequently, an enzyme-assisted deacetylation resulted in 
the chemo selective deprotection of the acetoxy group to produce 1,3-diacetyl- 
2-hydroxyindoles. However, a chemical deacetylation of 2-acetoxy-1,3-
diacetylinoles under mild basic or acidic conditions resulted in the formation 
of 3-acetyl-2-hydroxyindoles. 
N
O X
O
R'
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♣ Chang Qing Shi et al. [30] [2007] have designed A variety of indole 
derivatives then synthesized and preliminarily evaluated for their in vitro 
cytotoxic activity in the A431 and H460 cell lines. All the compounds 
examined conferred unusual potency in a tumor cell cytotoxicity assay. The 
findings showed the indole derivatives would be a promising candidate for the 
development of new anticancer agents. 
N
R 1
R 2
R 3
 
 
♣ Preeti Rani et al. [31] [2004] have  synthesised Chalcones of indole (1–5) and 
their corresponding products; pyrazolines (6–10) and azo compounds (11–15) 
and evaluated for their anti-inflammatory activity against carrageenan induced 
oedema in albino rats at a dose of 50 mg kg–1 oral. The structure of 
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compounds was confirmed by IR, 1H-NMR and mass spectral data. All the 
compounds of this series showed promising anti-inflammatory activity. The 
most active compound of this series is 3-[1-acetyl-5-(p-hydroxyphenyl)-2-
pyrazolin-3-yl] indole (7) was found to be most potent, which has shown 
higher percent of inhibition of oedema, lower ulcerogenic liability and acute 
toxicity than the standard drug phenylbutazone. 
N
H
O
R
  (1–5) 
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N N H
C H
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♣ Matthias Nettekoven et al. [32] [2001] have synthesised two indole derivative 
libraries. They have worked with 2-Acyl-3-amino-indoles (4) which could 
easily be accessed by treatment of the intermediates (3) with bases in a one-pot 
reaction sequence whereas the reaction of the isolated intermediates (5) 
(R3=aromatic-, heteroaromatic, or cycloalkyl) with acid chlorides yielded the 
novel indole derivatives (6). The products were purified by reversed phase 
column chromatography and obtained in multi-milligram quantities in 
acceptable yields. 
N
H
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♣ Mostafa Kiamehr et al. [33] [2009] have synthesised pentacyclic indole 
derivatives which was achieved via domino Knoevenagel-hetero-Diels–Alder 
reactions of indolin-2-thiones and O-propargylated salicylaldehyde derivatives 
in CH3CN in the presence of 10 mol % of ZnO as a heterogeneous catalyst. 
The products are formed in good to excellent yields. 
 
♣ Michele Giampieri et al. [34] [2009] have prepared Unsymmetrical methylene 
derivatives (5) following a known method, by reaction of the Mannich bases 
of 2-naphthols (4) with indoles. All synthesized compounds were tested 
against a wide panel of viruses, since previous work showed that Mannich 
bases on 7-hydroxycoumarin (1) and unsymmetrical methylene derivatives (2) 
were endowed with some antiviral activities. The symmetrical Mannich bases 
(4) were completely inactive, whereas the unsymmetrical methylene 
derivatives (5), although possessing a certain degree of toxicity, showed a 
significant activity against RSV. Some of compounds 5 showed a moderate 
antiviral activity against HIV-1, BVDV, YFV and CVB-2. The lack of activity 
of Mannich bases (4) demonstrates the crucial importance for antiviral activity 
of coumarin moiety present in Mannich bases (1). 
 
♣ Tetsuya Mochizuki et al. [35] [2010] have designed Indole derivatives (3a) 
and (3b) of adenophostin A (2) in which the adenine of 2 was replaced with 
indole or 4-fluoroindole as potential inositol trisphosphate receptor ligands. 
These target compounds were successfully synthesized from the key 
disaccharide unit (6). Biological evaluation showed that 3b selectively 
activates IP3R1, a subtype of IP3 receptors. 
 
 
♣ Rakesh Kumar Tiwari et al. [36] [2006] have synthesized A Series of 
substituted-10-methyl-1,2,3,4-tetrahydropyrazino [1,2-a] indoles derivatives 
and examined for their activity against pathogenic strains of Aspergillus 
fumigatus (ITCC 4517), Aspergillus flavus (ITCC 5192) Aspergillus niger 
(ITCC 5405) and Candida albicans (ITCC No 4718). All synthesized 
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compounds showed mild to moderate activity, except for 2-substituted-10-
methyl-1,2,3,4-tetrahydropyrazino [1,2-a] indoles (6a–d). The most active 1-
(4-chlorophenyl)-10-methyl-1,2,3,4-tetrahydropyrazino [1,2-a] indole (4c) 
exhibited a MIC value of 5.85 lg/disc against A. fumigatus and 11.71 lg/disc 
against A. flavus and A. niger in disc diffusion assay. Anti-Aspergillus activity 
of active compound (4c) by micro broth dilution assay was found to be 15.62 
lg/ml in case of Aspergillus fumigatus and 31.25 lg/ml with Aspergillus flavus 
and Aspergillus niger. The MIC90 value of the most active compound by 
percent germination inhibition assay was found to be 15.62 lg/ml against 
Aspergillus fumigatus. The MIC90 values of substituted-10-methyl-1,2,3,4-
tetrahydropyrazino [1,2-a] indoles against C. albicans ranged from 15.62 to 
250 lg/ml. The in vitro toxicity of the most active 1-(4-chlorophenyl)-10-
methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole 4c was evaluated using 
haemolytic assay, in which the compound was found to be non-toxic to human 
erythrocytes up to a concentration of 312.50 lg/ml. The standard drug 
amphotericin B exhibited 100% lysis at a concentration of 37.5 lg/ml. 
N N
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♣ Rakesh Kumar Tiwari et al. [37] [2006] have synthesized a series of 
substituted 1,2,3,4-tetrahydropyrazino [1,2-a] indole derivatives and tested 
against the Gram positive and Gram negative strains of bacteria namely 
Staphylococcus aureus (MTCCB 737), Salmonella typhi (MTCCB 733), 
Pseudomonas aeruginosa (MTCCB 741), Streptomyces thermonitrificans 
(MTCCB 1824) and Escherichia coli (MTCCB 1652). All synthesized 
compounds showed mild to moderate activity. Compounds (4d–f) were found 
to have potent activity against pathogenic bacteria used in the study. Their 
MIC ranged from 3.75 to 60 lg/disc. In vitro toxicity tests demonstrated that 
toxicity of (4d–f) was not significantly different than that of gentamycin. 
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However, at higher concentration (1000–4000 lg/ml) difference was highly 
significant. 
 
♣ Sandra Battaglia et al. [38] [1999] have prepared a number of indole amide 
derivatives bearing a basic side chain, in which the indole ring replaces the 
isoster benzimidazole nucleus typical of some well-known antihistamines, and 
tested for their H1-antihistaminic activity. The 1-benzyl-3- 
indolecarboxamides (32–42) showed antihistaminic (H1) activity (pA2 6–8) the 
3-indolylglyoxylylamides (7–16) and the 2-indolecarboxamides (48–56) 
showed little or no activity. Insertion of the basic side chain of the active 3-
indolecarboxamide derivatives into a piperazine ring (compounds 57–59) led 
to a dramatic loss of activity. All the active compounds proved to be 
competitive antagonists, since the values of the regression slope were not 
statistically different from (1). The most active compounds, 32, 33, 38–41, 
were also tested both in vitro for their anticholinergic activity and in vivo for 
their ability to antagonize histamine-induced cutaneous vascular permeability 
in rats.  
N
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AIM OF THE WORK 
 Coumarins are the compounds which posses a range of pharmacological 
activity like anti-HIV, antimicrobial, anticancer and anticoagulant. These 
pharmacological activities of coumarins have been revealed from literature review. 
 Literatures were also helpful to relate the coumarin and their novel derivatives 
called Bisindole substituted coumarins for their Antihyperlipidemic activity. 
 So the aim the present study could be divided as follows, 
♣ Synthesis of some new chemical entities of bisindole substituted 
coumarins having different groups. 
♣ Purification and characterization of the synthesised compounds based 
on their physical properties. 
♣ Characterization of the compounds based on the spectral data to 
elucidate their nature. 
♣ Evaluation of these compounds to check their Anti-hyperlipidemic 
potential. 
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PLAN OF THE WORK 
 The various Bisindole substituted coumarin derivatives were decided to 
synthesis and to evaluate their Antihyperlipidemic activity. 
 The plan of the present study could be briefed as follows, 
SCHEME 1 
 The scheme for the synthesis of various Bisindole substituted coumarin 
derivatives involves following steps. 
Step I 
 This involves the synthesis of α-napthol dialdehyde [II] from α-napthol [I] in 
the presence of hexamine (Hexamethylene tetramine-HMTA) with trifluoro acetic 
acid (TFA) and 10% sulphuric acid. This type of reaction is known as Duff reaction. 
Step II 
 In this step, the compound obtained in the first step that is α-napthol 
dialdehyde [II] was treated with diethyl malonate in the presence of ethanol and 
piperidine to get a coumarinic adduct [III] with aldehyde functional group. 
Step III 
 This step involves synthesis of different Bisindole substituted coumarin 
derivatives by treating various substituted indoles with coumarinic aldehyde 
compound [III] in the presence of Iodine and Acetonitrile. 
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SCHEME OF THE WORK 
General scheme 
 
 
 
Compound S1-S6 
 
 
OH
OH
CHO
CHO
O
O O
O
C2H5
CHO
i) HMTA/TFA, 100 oC, 3 hrs.
    ii) 10 % H2SO4, 100 
oC, 2 hrs. 
[I]
[II]
                          Different substituted inole
 i) Iodine
          ii) Acetonitrile
        Room temp.
[III]
naphthalen-1-ol
30 mins
ethyl 6-formyl-2-oxo-2H-benzo[h]chromene-3-carboxylate
  i) Diethyl malonate
 ii) Ethanol, piperidine
iii) Reflux 30 mins 
4-hydroxynaphthalene-1,3-dicarbaldehyde
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SCHEME FOR INDIVIDUAL SYNTHESIS 
Synthesis of Compound S1 
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Synthesis of Compound S2 
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K.M.College of pharmacy                                                                              SCHEME OF THE WORK 
 
Dept. of Pharmaceutical Chemistry Page 31 
Synthesis of Compound S3 
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Synthesis of Compound S4 
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Synthesis of Compound S5 
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Synthesis of Compound S6 
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EXPERIMENTAL WORK [39-44] 
 Experimental works of this thesis consists synthetic procedures, chemicals 
required, apparatus used and other laboratory works which are needed for this project. 
Apparatus and glass wares 
 These include Round Bottom (RB) flask, beaker, conical flask, reflux 
condenser, funnel, pipette, measuring cylinder, glass rod, separating funnel, 
thermometer, etc. 
Instruments used 
♣ Magnetic stirrer,  Melting point apparatus 
♣ FT-IR instrument (Perkin Elmer) 
♣ NMR instrument (Bruker) 
Chemicals used 
Step I 
♣ α-napthol [I] 
♣ Hexamine (Hexamethylene tetramine- HMTA) 
♣ Trifluoro acetic acid 
♣ 10% Sulphuric acid 
Step II 
♣ Napthol dialdehyde [II] obtained in step I 
♣ Diethyl malonate 
♣ Ethanol 
♣ Piperidine  
Step III 
♣ Coumarinic compound [III] obtained in step II 
♣ Different substituted indoles 
♣ Iodine  
♣ Acetonitrile  
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SYNTHETIC PROCEDURE 
STEP I 
 14.4g of α-napthol [I] (0.1M) was weighed and taken in 500 ml RB flask. To 
this 14g of hexamine (0.1M) and 80 ml of trifluoro acetic acid were added. Then this 
RB was fixed under reflux condenser. Then it was refluxed on boiling water bath for 3 
hours at 100° C. 
 After 3 hours of reflux, 10% sulphuric acid was to the reaction mixture. Then 
this was again refluxed under bath for 2 hours at 100° C the reddish brown napthol 
dialdehyde was formed in the reaction mixture. This was separated by extracting the 
mixture with ether. Then the ether was evaporated to obtain reddish brown colour 
napthol dialdehyde compound [II]. The yield of this compound was 12g. 
STEP II 
 About 10g of (0.05M) of napthol dialdehyde [II] obtained in step I was 
weighed and taken in a 500 ml RB flask. To this 8 ml of diethyl malonate (0.05M), 5 
ml ethanol and 5 ml of piperidine were added and shaked well. This reaction mixture 
was refluxed under water bath using reflux condenser for 30-40 minutes. Now the 
yellowish orange coumarinic adduct namely ethyl 6-formyl-2-oxo-2H-
benzo[h]chromene-3-carboxaldehyde [III] was formed. This was then separated 
carefully by filtration using suction funnel. The product of this was recrystallized by 
using methanol. Yield was about 10g. 
STEP III 
  The coumarinic compound obtained in step III was decided to use for the 
synthesis six various Bisindole substituted coumarin derivatives. By treating the 
coumarinic adduct with different substituted indoles in the presence of acetonitrile and 
iodine. This mixture was shaked for 30 minutes to get product. 
Compounds and their codes 
• Compound 1 [code-compound S1]   
• Compound 2 [code-compound S2]  
• Compound 3 [code-compound S3]   
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• Compound 4 [code-compound S4]  
• Compound 5 [code-compound S5]    
• Compound 6 [code-compound S6] 
 
PROCEDURE FOR INDIVIDUAL SYNTHESIS 
Synthesis of Compound S1 
 About 1.4g (0.005M) of coumarinic adducts [III] which was obtained in step 
III weighed and taken in RB flask. To this 1.45g of (0.01M) Indole-2-carboxaldehyde 
was added. Then 0.63g of iodine and 20 ml of acetonitrile were added. This mixture 
was then shaked well for 30 minutes at room temperature. The reddish brown crystals 
of compound S1 was separated by filtration. Recrystallization was done by using 
ethanol. The yield was about 1.2g. 
Synthesis of Compound S2 
 1.4g (0.005M) of coumarinic adducts [III] was weighed and taken in RB flask. 
To this 1.45g of (0.01M) Indole-4-carboxaldehyde was added. Then 0.63g of iodine 
and 20 ml of acetonitrile were added. This mixture was then shaked well for 30 
minutes at room temperature. The reddish powders of compound S2 was separated by 
filtration. Recrystallization was done by using ethanol. The yield was about 0.86g.  
Synthesis of Compound S3 
 About 1.4g (0.005M) compound [III] which was obtained in step III weighed 
and taken in RB flask. To this 1.61g of (0.01M) Indole-2-carboxylic acid was added. 
Then 0.63g of iodine and 20 ml of acetonitrile were added. This mixture was then 
shaked well for 30 minutes at room temperature. The orange colour compound S3 was 
separated by filtration. Recrystallization was done by using chloroform. The yield was 
about 0.98g.  
Synthesis of Compound S4 
 About 1.4g (0.005M) of coumarinic adducts [III] which was obtained in step 
III weighed and taken in RB flask. To this 1.61g of (0.01M) Indole-4-carboxaylic acid 
was added. Then 0.63g of iodine and 20 ml of acetonitrile were added. This mixture 
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was then shaked well for 30 minutes at room temperature. The brown crystals of 
compound S4 was separated by filtration. Recrystallization was done by using 
chloroform. The yield was about 0.89g. 
Synthesis of Compound S5 
 About 1.4g (0.005M) of coumarinic compound [III] was weighed and taken in 
RB flask. To this 1.g of (0.01M) Indole-5-carbonitrile was added. Then 0.63g of 
iodine and 20 ml of acetonitrile were added. This mixture was then shaked well for 30 
minutes at room temperature. The yellowish white crystals of compound S5 was 
separated by filtration. Recrystallization was done by using methanol. The yield was 
about 0.74g. 
Synthesis of Compound S6 
 About 1.4g (0.005M) of coumarinic adducts [III] which was obtained in step 
III weighed and taken in RB flask. To this 1.45g of (0.01M) Indole-5-carboxamide 
was added. Then 0.63g of iodine and 20 ml of acetonitrile were added. This mixture 
was then shaked well for 30 minutes at room temperature. The pale yellow powders of 
compound S6 was separated by filtration. Recrystallization was done by using ethyl 
acetate. The yield was about 1.3g.  
Purification of the compounds 
 The synthesised compounds were purified by recrystallization using 
appropriate solvent like Methanol, Ethanol, Chloroform and Ethyl acetate. 
 Identification compounds 
 Identification of the products obtained in each steps and final compounds have 
done Thin Layer Chromatography (TLC) using appropriate solvent system as mobile 
phase and silica gel G as stationary phase. 
Preparation of TLC plates 
 Silca gel G and water were measured at the ratio of 1g: 2.5ml and mixed 
together until to form slurry. This slurry of silica gel was poured evenly on the glass 
plate to make 1mm thickness. These plates were air dried and kept inside the hot air 
oven at the temperature of 100°C for 40 minutes. These were taken out prior to use.  
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Calculation of Rf values 
 After every step of the reactions, the starting material and the reaction mixture 
were spotted on the TLC plates. Then this plate was air dried and kept in the mobile 
phase chamber. Now these spots were allowed to travel 1/4th of the plate height. Then 
plates were taken out and dried. The distance was measured and the Rf values are 
calculated as follows. 
    ܴ݂ ݒ݈ܽݑ݁ ൌ ୢ୧ୱ୲ୟ୬ୡୣ ୲୰ୟ୴ୣ୪୪ୣୢ ୠ୷ ୱ୭୪୳୲ୣ
ௗ௜௦௧௔௡௖௘ ௧௥௔௩௘௟௟௘ௗ ௕௬ ௦௢௟௩௘௡௧
 
 Difference in the Rf values of starting material and product (reaction mixture) 
indicated the completion of reaction. The Rf values have also been determined for all 
individual synthesised compounds. 
Solubility 
 The solubility of synthesised compounds was also checked by using different 
solvent like water, methanol, ethanol and DMSO. 
Melting point determination 
 The melting points of the synthesised compounds were checked using melting 
point apparatus. In this powder compounds were filled in the bottom closed capillary 
tube. These tubes were then kept into melting point apparatus in which the liquid 
paraffin was boiling. To this thermometer was also inserted. Now the temperature at 
where the compounds get started to melt was noted in thermometer. Thus the melting 
points of each compound were detected. 
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CHARACTERIZATION OF COMPOUNDS 
STRUCTURES 
Compound S1 
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Compound S4 
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PHYSICAL CHARECTERS 
1. Molecular formula, molecular weight and yield of the compounds  
TABLE NO.1 
Data for Molecular formula, molecular weight and yield % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage yield calculation 
 ܲ݁ݎܿ݁݊ݐܽ݃݁ ݕ݈݅݁݀ ൌ ௉௥௔௖௧௜௖௔௟ ௬௜௘௟ௗ ௬௜௘௟ௗ 
்௛௘௢௥௜௧௜௖௔௟ ௬௜௘௟ௗ
ൈ 100 
 
 ݄ܶ݁݋ݎ݅ݐ݈݅ܿܽ ݕ݈݅݁݀ ൌ ݉݋݈݁ ݒ݈ܽݑ݁ ൈ ݉݋݈݁ܿݑ݈ܽݎ ݓ݄݁݅݃ݐ ݋݂ ݌ݎ݋݀ݑܿݐ  
 
S.No Compound 
names 
Molecular 
formula 
Molecular 
weight 
Percentage 
yield 
 
1 
 
S1 
C35 H24 N2 O6 568 42.56% 
 
2 
 
S2 
C35 H24 N2 O6 568 28.37% 
 
3 
 
S3 
C35 H24 N2 O8 600 32.90% 
 
4 
 
S4 
C35 H24 N2 O8 600 29.88% 
 
5 
 
S5 
C35 H22 N4 O4 562 26.52% 
 
6 
 
S6 
C35 H26 N4 O6 598 43.80% 
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2. Colour, appearance and melting points of the compounds 
 
TABLE NO. 2 
Data for Colour, Appearance and Melting Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument for melting point detection 
♣ Instrument used : Melting point apparatus 
♣ Model   : Veego – VMP (Silicon oil bath) 
♣ Method  : Open capillary method 
   
 
 
 
 
 
 
S. No Compound name Colour 
Appearance 
state 
Melting 
point 
°C 
1 S1 
Reddish 
brown 
Crystalline 
powder 182-184 
2 S2 Red Powder 193-195 
3 S3 Orange 
Course 
powder 247-249 
4 S4 Brown Powder 234-236 
5 S5 
Yellowish 
white 
Course 
powder 176-178 
6 S6 Pale yellow 
Course 
powder 212-215 
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3. Solubility of compounds in different solvents 
TABLE NO. 3 
 
Data for the Solubility of Compounds 
 
 
 
 
 
- Indicates insoluble 
+    Indicates soluble 
-+   Indicates partially soluble 
 
  
 
 
 
S. No Compound name 
Solubility in solvents 
Water Methanol Ethanol chloroform 
1 S1 - + - + - + 
2 S2 - + - + - + 
3 S3 - - + - + + 
4 S4 - - + - + + 
5 S5 - + + - + 
6 S6 - + + - + 
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4. TLC parameters 
 The Rf value of synthesised compounds have been found out using appropriate 
solvents system. 
  Adsorbent or stationary phase : Silica gel G 
  Developing Solvent or Mobile phase : Ethanol and Chloroform 
  Detecting agent   : Iodine vapour 
  Colour of the spots   : Yellow [for S1 S5 S6]  
            Brown [for S2 S3 S4]  
 
TABLE NO. 4 
Data showing Rf values of compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
S.No Compound Adsorbent Mobile phase &  ratio Rf value 
1 S1 
Silica gel 
G 
Ethanol : chloroform 
6 : 4 0.68 
2 S2 
Ethanol : chloroform 
8 : 2 0.73 
3 S3 
Chloroform : benzene 
7 : 3 0.62 
4 S4 
Chloroform : benzene 
6 : 4 0.79 
5 S5 
Ethanol : hexane 
5 : 5 0.70 
6 S6 
Ethanol : hexane 
3 : 7 0.59 
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INTERPRETATION OF SPECTRA 
Compound S1 
IR Interpretation 
   Instrument  : FT-IR instrument 
   Name   : Perkin Elmer 
   Method  : KBr pellet 
 
O
O
OEt
O
N H N H
CHO OHC  
 
TABLE NO. 5 
 
IR Spectral data for Compound S1 
 
S. No Frequency cm-1 Groups assigned 
1 3747.89 Due to N-H stretching 
2 2929.97 Due to C-H stretching (aromatic) 
3 2366.96 Due to C-H stretching 
4 1637.36 Due to C-O stretching (aldehyde) 
5 1297.90 Due to C-O stretching 
6 998.60 Due to C-H bending (opposite) 
7 834.76 Due to N-H bending (opposite) 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : MeOD 
 
TABLE NO. 6 
 
1H NMR spectral data for compound S1 
 
S. No Signal value  (δ ppm) Group assigned 
1 3.3042 Singlet, CH proton adjacent to -OCOAr 
2 3.3753-5.1848 Singlet, CH proton adjacent to -OCOAr 
4 6.7659-7.1884 Singlet, aromatic protons 
5 7.4044-7.9429 Singlet, aromatic protons 
6 8.4811-8.5722 Singlet, NH protons 
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Compound S2 
Structure  
O
O
OEt
O
N
H
N
H
CHO CHO
 
 
TABLE NO. 7 
 
IR Spectral data for Compound S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Frequency cm-1 Groups assigned 
1 3293.13 Due to N-H stretching 
2 2923.53 Due to C-H stretching (asymmetric) 
3 2850.90 Due to C-H stretching (symmetric) 
4 2365.67 Due to C-H stretching 
5 1464.46 Due to C-H bending (sp3) 
6 1123.53 Due to  C-O stretching 
7 1064.05 Due to  C-O stretching 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : MeOD 
 
TABLE NO. 8 
 
1H NMR spectral data for compound S2 
 
S. No Signal value  (δ ppm Group assigned 
1 3.3842-5.1748 Singlet, CH proton adjacent to -OCOAr 
2 6.7959-7.4241 Singlet, aromatic protons 
3 7.8589-7.9429 Singlet, aromatic protons 
4 8.4233-8.5234 Singlet, NH protons 
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Compound S3 
Structure  
O
O
OEt
O
NH NH
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TABLE NO. 9 
 
IR Spectral data for Compound S3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Frequency cm-1 Groups assigned 
1 3757.72 Due to N-H stretching 
2 3431.72 Due to N-H stretching 
3 2956.52 Due to C-H stretching (asymmetric) 
4 2870.59 Due to C-H stretching (symmetric) 
5 1635.49 Due to C-O stretching 
6 1592.89 Due to C=C stretching (aromatic) 
7 1431.93 Due to C-H bending (opposite) 
8 955.29 Due to C-H bending (aromatic) 
9 848.5 Due to N-H bending 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : MeOD 
 
TABLE NO. 10 
 
1H NMR spectral data for compound S3 
 
S. No Signal value  (δ ppm Group assigned 
1 1.3015- 1.4284 Singlet CH3 proton 
2 1.5602-1.7295 Singlet CH3 proton 
3 3.3029-3.6429 Singlet CH proton adjacent to -OCOAr 
4 4.8556 Singlet CH proton adjacent to -OCOAr 
5 7.0506-7.3049 Multiplet, aromatic proton 
6 7.5228-7.5431 Multiplet, aromatic proton 
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Compound S4 
Structure 
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TABLE NO. 11 
 
IR Spectral data for Compound S4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Frequency cm-1 Groups assigned 
1 3754.13 Due to N-H stretching 
2 3446.54 Due to N-H stretching 
3 2923.97 Due to C-H stretching (asymmetric) 
4 2854.14 Due to C-H stretching (symmetric) 
5 1627.14 Due to C-O stretching 
6 1440.51 Due to C-H bending 
7 1030.76 Due to C-O stretching 
8 748.58 Due to N-H bending 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : MeOD 
 
TABLE NO. 12 
 
1H NMR spectral data for compound S4 
 
S. No Signal value  (δ ppm Group assigned 
1 1.3147-1.711 Singlet, CH3 proton 
2 3.3029-3.6354 Singlet, CH proton 
3 7.0321-7.5225 Singlet, aromatic proton 
4 8.4811-8.5788 Singlet, NH proton 
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Compound S5 
Structure 
O
O
OEt
O
N
H
N
H
NC CN
 
 
TABLE NO. 13 
 
IR Spectral data for Compound S5 
 
S. No Frequency cm-1 Groups assigned 
1 3755.66 Due to N-H stretching 
2 3428.21 Due to N-H stretching 
3 2924.67 Due to C-H stretching (asymmetric) 
4 2854.92 Due to C-H stretching (symmetric) 
5 1599.70 Due to C-O stretching 
6 1439.67 Due to C-H bending 
7 1025.54 Due to C-O stretching 
8 747.38 Due to N-H bending 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : MeOD 
 
TABLE NO. 14 
 
1H NMR spectral data for compound S5 
 
S. No Signal value  (δ ppm Group assigned 
1 1.3825-1.7349 Singlet, CH3 proton 
2 2.2711-2.3817 Singlet CH2 proton 
3 3.2978-4.8834 Singlet CH proton adjacent to –OCOAr 
4 7.0531-7.5424 Singlet, aromatic proton 
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Compound S6 
Structure      
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TABLE NO. 15 
 
IR Spectral data for Compound S6 
 
S. No Frequency cm-1 Groups assigned 
1 3755.09 Due to N-H stretching 
2 3447.24 Due to  N-H stretching 
3 2922.59 Due to C-H stretching (asymmetric) 
4 2853.66 Due to C-H stretching (symmetric) 
5 1728.17 Due to C-O stretching 
6 1562.09 Due to N-H bending (amide) 
7 1436.24 Due to C-H stretching 
8 1030.92 Due to C-N stretching 
9 934.97 Due to C-H bending (opposite) 
10 745.27 Due to N-H bending 
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1H NMR interpretation 
 
   Instrument   : 1H NMR spectrophotometer 
   Name    : Bruker 
   Solvent used  : CDCl3 
 
TABLE NO. 16 
 
1H NMR spectral data for compound S6 
 
S. No Signal value  (δ ppm Group assigned 
1 1.3914-2.3634 Singlet, CH3 proton 
2 3.3020-3.339 Singlet CH proton adjacent to –OCOA 
3 7.2617-7.5424 Singlet, aromatic proton 
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HYPOLIPIDEMIC ACTIVITY OF VARIOUS SYNTHETIC DRUGS IN 
HYPERLIPIDEMIC MODELS OF WISTAR ALBINO RATS [45-53] 
 
 
INTRODUCTION: 
Many people with diabetes have conditions called “risk factor” that contribute to 
atherosclerosis and its complications. These include high blood pressure, excess weight 
and high blood glucose levels. Dyslipidemia further raises risk of atherosclerosis in 
people with diabetes.   Dyslipidemia affects people with type 2 diabetes more often than 
those with type 1 diabetes. The most common Dyslipidemia in diabetes is the 
combination of high triglycerides and low HDL levels. People with diabetes may also 
have elevated LDL cholesterol.   
Among the drugs available to treat Dyslipidemia, statins are often the first choice 
for lowering total and LDL cholesterol levels, other drugs that lowers cholesterol include 
cholesterol-adsorption blockers, bile acids, sequestrants, and nicotinic acids. These may 
be used in combination, if a single drug is not effective in reaching target levels. Fibrates 
and extended release niacin may be used to lower triglycerides (or) raise HDL cholesterol 
levels [1].  
Hyperglycemia and Dyslipidemia are significant and independent risk factors for 
the vascular complications and suggested to cause cardio vascular pathological changes 
in diabetic states through the following molecular mechanism, formation and 
accumulation of advanced glycation products, increased oxidative stress, activation of 
proteinkinase C pathway, increased activity of hexosamine pathway and vascular 
inflammation and the impairment of insulin action in the vascular tissues [2]. In the 
present study an attempt has been made to screen the various synthetic drugs for the 
Hypolipidemic activity. 
 The present investigation is undertaken to study the effect of various synthetic 
drugs on changes in Total cholesterol, Triglycerides, HDL, LDL, VLDL, AI, and 
LDL/HDL. 
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Materials and methods 
Animals 
Male albino strains of wistar rats were obtained from central animal house, 
K.M.College of pharmacy, Madurai. The animals were given standard rodent diet and 
water ad libitum throughout the study. The rats used in the present study were 
maintained in accordance with guidelines of the national institute of nutrition, Indian 
council for medical research, Hyderabad, India and study approved by Institutional 
animal ethical committee. 
 
Materials: 
• Various synthetic drugs such as S1 to S6  
• Cholesterol extra pure for feeding purpose was obtained from S.D fine-chem. 
limited, Mumbai, India. Coconut oil was used as a vehicle for cholesterol 
feeding. 
• Atorvastatin was obtained from Micro labs, Bangalore, India. 
 
Experimental procedure:  
 All the animals were weighed and divided into nine  groups each of six animals.  
Group I : Normal control.  
Group II : Cholesterol control. Fed cholesterol at a dose of 400mg/kg body weight 
for 30 days.  
Group III : fed cholesterol as in group II and Atorvastatin 1mg/kg body weight 
from days 15 to day 30.[3] 
Group IV : fed cholesterol as in group II and synthetic compound S1 at  a dose of 
50mg/kg body weight from days 15 to day 30. 
K.M.College of Pharmacy                                                                           PHARMACOLOGICAL STUDY 
 
Dept. of Pharmaceutical Chemistry Page 60 
 
Group V : fed cholesterol as in group II and synthetic compound S2 at a dose of 
150mg/kg body weight from days 15 to day 30. 
Group VI : fed cholesterol as in group II and synthetic compound S3 at a dose of 
50mg/kg body weight from days 15 to day 30. 
Group VII : fed cholesterol as in group II and synthetic compound S4 at a dose of 
50mg/kg body weight from days 15 to day 30. 
Group VIII : fed cholesterol as in group II and synthetic compound S5 at a dose of 
50mg/kg body weight from days 15 to day 30. 
Group IX : fed cholesterol as in group II and synthetic compound S6 at a dose of 
50mg/kg body weight from days 15 to day 30. 
 At the end of 30 days all the rats were sacrificed, blood was collected, allowed 
to clot and serum was obtained by centrifugation. The serum samples were used for 
various biochemical procedures. 
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Biochemical analysis: 
 The serum was analyzed for total cholesterol, triglycerides, high density 
lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein 
(VLDL), by using standard protocol methods. (Auto Analyzer) 
Atherogenic index (AI) and LDL-C/HDL-C ratio
• The AI was calculated by the following formula 
• AI = (total cholesterol – HDL-C)/HDL-C 
• LDL-C/HDL-C ratio was calculated as the ratio of plasma LDL-C to HDL-C  
Levels 
Statistical analysis 
• All the values were expressed as mean ± SEM.  
• Data was analyzed by one way analysis of variance (ANOVA) followed by 
Newman keul’s multiple range tests. 
• P values <0.05 were considered as statistically significant. 
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Table 1: Effect of various synthetic drugs on Lipid Profile 
GROUPS 
Total 
cholesterol 
(Mg/dl) 
Tri 
glycerides 
(mg/dl) 
HDL  
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
AI 
LDL/ 
HDL 
Normal 
Control 
52.60 ± 
2.75 
57.10± 
2.89 
26.40 ± 
1.16 
14.30 ± 
0.70 
31.88 ± 
1.58 
0.99 ± 
1.37 0.54 
Cholesterol 
Control 
115.40 ± 
4.50**(a) 
160.4 ± 
5.68**(a) 
11.90 ± 
0.65**(a) 
31.95 ± 
1.86**(a) 
13.10 ± 
0.70**(a) 
8.69 ± 
5.92**(a) 2.68 
Standard 
Control 
73.65± 
3.52**(b) 
80.8 ± 
3.78**(b) 
21.8 ± 
1.06**(b) 
21.01 ± 
1.04**(b) 
26.90 ± 
0.92**(b) 
2.37 ± 
2.32**(b) 0.96 
Treatment 
control  
(S1) 
90.80 ± 
3.75**(b) 
118.42 ± 
4.90**(b) 
18.2 ± 
0.90**(b) 
25.23 ± 
1.58**(b) 
19.90 ± 
0.45**(b) 
3.98 ± 
3.16**(b) 1.38 
Treatment 
control 
(S2) 
88.90 ± 
2.94**(b) 
94.3 ± 
3.77**(b) 
20.22 ± 
1.20**(b) 
22.08 ± 
1.12**(b) 
21.20 ± 
0.88**(b) 
3.39 ± 
1.45**(b) 1.09 
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Table 2: Effect of various synthetic drugs on Lipid Profile 
GROUPS 
Total 
cholesterol 
(Mg/dl) 
Tri 
glycerides 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
AI 
LDL/ 
HDL 
Treatment 
control 
(S3) 
85.83 ± 
2.82**(b) 
96.4 ± 
3.80**(b) 
19.32 ± 
1.30**(b) 
20.15 ± 
1.72**(b) 
23.30 ± 
0.96**(b) 
3.44 ± 
1.16**(b) 1.04 
Treatment 
control 
(S4) 
83.80 ± 
2.65**(b) 
98.6 ± 
3.92**(b) 
21.30 ± 
1.42**(b) 
20.35 ± 
1.62**(b) 
22.35 ± 
0.86**(b) 
3.13 ± 
2.93**(b) 0.95 
Treatment 
control 
(S5) 
85.90 ± 
2.90**(b) 
92.0 ± 
3.07**(b) 
20.32 ± 
1.08**(b) 
21.42 ± 
1.82**(b) 
23.32 ± 
0.98**(b) 
3.22 ± 
1.68**(b) 1.05 
Treatment 
control 
(S6) 
87.80 ± 
2.98**(b) 
94.8 ± 
3.12**(b) 
21.55 ± 
1.35**(b) 
22.42 ± 
1.72**(b) 
22.86 ± 
0.95**(b) 
3.07 ± 
1.20**(b) 1.04 
 
 
 
 
• Values are expressed as Mean ± SEM. 
• Values were find out by using ONE WAY ANOVA followed by Newman Keul’s 
multiple range tests. 
• ** (a) values were significantly different from normal control at P< 0.01. 
• ** (b) Values were significantly different from hyperlidemic control at P< 0.01. 
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RESULTS 
 Table 1 and 2 shows the levels of Cholesterol, Triglycerides, HDL, LDL and 
VLDL of control and experiment rats respectively. Serum of hyperlipidemic rats showed 
significantly increased levels of Cholesterol, Triglycerides, LDL - C and low HDL – C, 
when compared with normal rats. In rats treated with various synthetic drugs and 
Atorvastatin there was significant decrease in the content cholesterol, TGs, LDL – C, and 
VLDL and increases HDL – C, when compared with cholesterol control rats. 
 
Atherogenic index (AI) and LDL – C / HDL – C ratio: 
 
 Table 1 and 2 shows the changes of Atherogenic Index and LDL – C / HDL – C 
ratio in control and treated rats. It appears clear form these results that the cholesterol 
induction significantly affects the cardio vascular risk markers. 
 Indeed, AI was statistically increased in cholesterol control group 90% compared 
with the values found in their normal control group. 
 Besides there were significant further increase of LDL – C / HDL – C ratio in 
cholesterol control group compared to normal control group. 
 Promising results in lowering of AI by various synthetic drugs that is bis indole 
substituted coumarin derivatives was found in Table 1 and 2. The various synthetic drugs 
showed an improvement of the cardio vascular risk level by decrease of AI in the treated 
groups when compared to the cholesterol control group. 
 The ratio of LDL – C to HDL – C is also a protective indicator of cardio vascular 
disease incidence. The cholesterol induction produced a significant increase of this 
marker. In contrast, elevated ratio in treated group and Atorvastatin group returned to 
basal value when the data were compared in the same period to the data found for 
cholesterol rats. (Table 1 and 2) 
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RESULTS AND DISCUSSION 
 This work started with synthesis of novel bisindole substituted coumarin 
derivatives by conventional method. By this method the compounds have been 
synthesised. 
• Compound 1 [code-compound S1]   
• Compound 2 [code-compound S2]  
• Compound 3 [code-compound S3]   
• Compound 4 [code-compound S4]  
• Compound 5 [code-compound S5]    
• Compound 6 [code-compound S6] 
Characteristics of Compounds 
 The synthesised compounds were subjected to check their characters like 
melting point, solubility, Rf  value and spectral data. 
Melting point 
 Melting points these compounds were determined by using melting point 
apparatus. Melting points of individual compounds were checked in each step and 
differ from the parent compound which conformed that reactions were completed and 
product has formed. 
Rf  value determination 
 The difference in the Rf values of individual compounds shown that products 
were formed and these compounds were different compound. 
IR interpretation 
 An interpretation of IR spectra of individual compounds showed their 
respective functional groups. Presence of expected peaks proved that reactions have 
been completed. 
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1H NMR data 
 Interpretation of the 1H NMR data showed that the synthesised compounds 
have specific nature of protons in their structure. 
ANTI-HYPERLIPIDEMIC ACTIVITY 
The reduction of plasma total cholesterol was associated with a decrease in its 
LDL fraction which is a major, potentially modifiable risk factor of cardio vascular 
disease and the target of drug. Many suggest that the cholesterol lowering activity of 
this product appears to be due to the enhancement of LDL – C catabolism through 
hepatic receptors [4].  
In addition various synthetic drugs showed protective action which is reported 
to have a preventive function against atherogenesis since an independent inverse 
relationship between blood HDL – C levels and cardio vascular risk incidence is 
reported [5].  
The lipoprotein called “good cholesterol” facilitates the mobilization of 
triglycerides and cholesterol from plasma to liver where it is catabolised and 
eliminated in the form of bile acids. The possible mechanism of this activity may 
result from the enhancement of lecithin cholesteryl acyl transferase (LCAT) and 
inhibition of Hepatic Triglyceride Lipase (HTL) on HDL which may lead to a rapid 
catabolism of blood lipids through enterohepatic tissues [6]. 
It is also recently reported that triglycerides plays a key role in the regulation 
of lipoprotein interaction to maintain normal lipid metabolism. Indeed, the elevated 
plasma TG levels were associated with an increased incidence of coronary artery 
disease.   
Moreover these higher plasma TG levels have been attributed mainly to 
increase population of small, dense LDL deposits which are very atherogenic  and 
enhanced cholesteryl ester mass transfer from apolipoprotein B containing 
lipoproteins (VLDL and LDL)[7]. TG has also been proposed to be major determinant 
of cholesteryl esterification, its transfer and HDL remodeling in human plasma [8]. 
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various synthetic drugs significantly suppress the elevated blood concentration 
of TGs. This result suggests that the product is able to restore, at least partially, the 
catabolism of TG. The underlying the mechanism of this activity is not elucidated by 
the present study. However, as hypothesized by many works with other plants, the 
restoration of catabolic mechanism of TGs would be due to an increased stimulation 
of the lipolytic activity of Plasma Lipoprotein Lipase (LPL) [9]. 
 Administration of various synthetic drugs provides a beneficial action on rat 
lipid metabolism with regard to the reduction of AI. Infact, the AI was decreased in all 
treated groups. It is also desirable to have higher plasma HDL and lower LDL – C to 
prevent atherogenesis, since there is a positive correlation between an increased LDL 
– C / HDL – C ratio and the development of atherosclerosis. Again, the administration 
of various synthetic drugs significantly suppress the higher values of LDL – C / HDL 
– C ratio showing the beneficial effect of this plant in preventing atherosclerosis 
incidence. 
 
 
K.M.College of Pharmacy                                                                                                 CONCLUSION 
 
Dept. of Pharmaceutical Chemistry Page 68 
 
CONCLUSION 
SYNTHESIS 
 From the physical characteristics and spectral data of compound S1 – S6 
showed that the synthesised compounds were our expected substituted compounds. So 
these were selected to study their anti-hyperlipidemic potential. 
 So it was concluded that synthetic reactions were completed and yielded our 
final compounds. 
PHARMACOLOGICAL STUDY 
Hyperlipidemia is considered to be major risk factor for the premature 
atherosclerosis and essentially the cholesterol in atherosclerotic plaque is derived 
from that of circulatory cholesterol. The antihyperlipidemic effect of various synthetic 
drugs of bisindole substituted coumarin could be considered as a possible therapeutic 
value.  
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